2-acetamido-5-ethynylpyridine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-acetamido-5-ethynylpyridine
• 英文别名: N-(5-ethynyl-pyridin-2-yl)-acetamide；N-(5-Ethynylpyridin-2-YL)acetamide
• 化学式: C₉H₈N₂O
• 分子量: 160.175
• InChiKey: QEVXCIDPJKAEMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-acetamido-5-ethynylpyridine 在 copper(l) iodide 、 四(三苯基膦)钯 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 20.16h， 生成
  参考文献：
  名称：

  Synthesis and evaluation of aminopyridine derivatives as potential BACE1 inhibitors

  摘要：

  To identify a new non-peptidyl BACE1 inhibitor, we focused on the aminopyridine structure, which binds to the active sites of BACE1. Synthesis of aminopyridine derivatives and evaluation of inhibitory activity against rBACE1 are described. The 2-aminopyridine moiety and/or 3-methoxybenzaldehyde could be converted to terminal acetylene derivatives by the Sonogashira method. Sonogashira or Glaser cross-coupling reactions with the corresponding derivatives followed by hydrogenation could derive the designed compounds. Although inhibitory activities of the synthetic compounds against rBACE1 were weak, the aminopyridine motif has potential as a BACE1 inhibitor. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.10.007
• 作为产物：
  描述：

  2-氨基-5-碘吡啶 在 吡啶 、 4-二甲氨基吡啶 、 copper(l) iodide 、 四(三苯基膦)钯 、 四丁基氟化铵 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 48.5h， 生成 2-acetamido-5-ethynylpyridine
  参考文献：
  名称：

  Synthesis and evaluation of aminopyridine derivatives as potential BACE1 inhibitors

  摘要：

  To identify a new non-peptidyl BACE1 inhibitor, we focused on the aminopyridine structure, which binds to the active sites of BACE1. Synthesis of aminopyridine derivatives and evaluation of inhibitory activity against rBACE1 are described. The 2-aminopyridine moiety and/or 3-methoxybenzaldehyde could be converted to terminal acetylene derivatives by the Sonogashira method. Sonogashira or Glaser cross-coupling reactions with the corresponding derivatives followed by hydrogenation could derive the designed compounds. Although inhibitory activities of the synthetic compounds against rBACE1 were weak, the aminopyridine motif has potential as a BACE1 inhibitor. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.10.007

文献信息

• [EN] NOVEL GALACTOSIDE INHIBITOR OF GALECTINS<br/>[FR] NOUVEL INHIBITEUR GALACTOSIDE DE GALECTINES
  申请人：GALECTO BIOTECH AB

  公开号：WO2016113335A1

  公开（公告）日：2016-07-21

  The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

  本发明涉及一种通式（1）的化合物。通式（1）的化合物适用于治疗与在哺乳动物（如人类）中的一个半乳凝集素（例如半乳凝集素-3）与配体结合有关的疾病的方法。此外，本发明涉及一种治疗与在哺乳动物（如人类）中的一个半乳凝集素（例如半乳凝集素-3）与配体结合有关的疾病的方法。
• Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
  申请人：——

  公开号：US20020103203A1

  公开（公告）日：2002-08-01

  Amide compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  描述了调节和/或抑制特定蛋白激酶活性的酰胺化合物。这些化合物和含有它们的药物组合物能够介导酪氨酸激酶信号传导，以调节和/或抑制不需要的细胞增殖。该发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予这些化合物的有效量来治疗癌症以及与不需要的血管生成和/或细胞增殖相关的其他疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣的方法。
• Hydrogen-bond driven assembly of a molecular capsule facilitated by supramolecular chelation
  作者：Christer B. Aakeröy、Arbin Rajbanshi、John Desper

  DOI：10.1039/c1cc14124d

  日期：——

  Resorcinarene-based cavitands functionalized with acetamido groups capable of self-complementary hydrogen-bond interactions, were synthesized in order to construct supramolecular capsules. The 1,3-bifunctionalized cavitand produced a polymeric assembly, whereas the tetra-functionalized analogue yielded a discrete capsule held together via N-H...O hydrogen bonds. The ethynyl species attached to the

  为了构建超分子胶囊，合成了以乙酰氨基官能化的基于间苯二甲烯的空洞体，该乙酰氨基基团能够自我互补的氢键相互作用。1,3-双官能化的空洞分子产生了聚合物组装体，而四官能化的类似物产生了通过NH ... O氢键结合在一起的离散胶囊。附着在这些宿主分子边缘的乙炔基物质加深了每个空洞，并扩大了所得胶囊的体积。
• Acetylenic heteroaryl compounds
  申请人：Wang Yihan

  公开号：US08461167B2

  公开（公告）日：2013-06-11

  This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.

  本发明涉及一般式化合物：其中变量基团如此定义，以及它们的制备和使用。
• Acetylenic Heteroaryl Compounds
  申请人：Wang Yihan

  公开号：US20130018046A1

  公开（公告）日：2013-01-17

  This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.

  本发明涉及通式如下的化合物：其中变量基团如本文所定义，以及它们的制备和使用。